Dtsch Med Wochenschr 2014; 139(05): 193-206
DOI: 10.1055/s-0033-1359874
CME | Review article
Gastroenterologie, Onkologie
© Georg Thieme Verlag KG Stuttgart · New York

Das kolorektale Karzinom

Colorectal cancer
C. P. Pox
1   Medizinische Klinik, Knappschaftskrankenhaus Ruhr-Universität Bochum
,
W. Schmiegel
1   Medizinische Klinik, Knappschaftskrankenhaus Ruhr-Universität Bochum
› Author Affiliations
Further Information

Publication History

05 May 2013

26 September 2013

Publication Date:
21 January 2014 (online)

 
  • Literatur

  • 1 Al-Sukhni E, Milot L, Fruitman M et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol 2012; 19: 2212-2223
  • 2 Andre T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116
  • 3 Arnold D, Seufferlein T. Targeted treatments in colorectal cancer: state of the art and future perspectives. Gut 2010; 59: 838-858
  • 4 Biagi JJ, Raphael MJ, Mackillop WJ et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer. A systemic review and meta-analysis. JAMA 2011; 305: 2335-2342
  • 5 De Jong MC, Pulitano C, Ribero D et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis. Ann Surg 2009; 250: 440-448
  • 6 Gill S, Loprinzi CL, Sargent DJ et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. J Clin Oncol 2004; 22: 1797-1806
  • 7 Gray R, Barnwell J, McConkey C et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020-2029
  • 8 Haller DG, Tabernero J, Maroun J et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011; 29: 1465-1471
  • 9 Hewitson P, Glasziou P, Watson E et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008; 103: 1541-1549
  • 10 Jasperson KW, Tuohy TM, Neklason DW et al. Hereditary and familial colon cancer. Gastroenterology 2010; 138: 2044-2058
  • 11 Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2007; (01) CD002200
  • 12 Lee SJ, Boscardin WJ, Stijacic-Cenzer I et al. Time lag to benefit after screening for breast and colorectal cancer: meta-analysis of survival data from the United States, Sweden, United Kingdom and Denmark. BMJ 2012; 345: e8441
  • 13 Liang Y, Li G, Chen P et al. Laparoscopic versus open colorectal resection for cancer: a meta-analysis of results of randomized controlled trials on recurrence. Eur J Surg Oncol 2008; 34: 1217-1224
  • 14 Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer?. J Clin Oncol 2008; 26: 303-312
  • 15 Puli SR, Bechtold ML, Reddy JB et al. Can endoscopic ultrasound predict early rectal cancers that can be resected endoscopically? A meta-analysis and systematic review. Dig Dis Sci 2010; 55: 1221-1229
  • 16 Pox C, Aretz S, Bischoff SC et al. S3-Leitlinie kolorektales Karzinom. Z Gastroenterol 2013; 51: 753-854
  • 17 Robert Koch-Institut. Krebs in Deutschland 2007/2008. . 8. Ausgabe. Berlin: Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg); 2012
  • 18 Rothwell PM, Fowkes FG, Belch JF et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31-41
  • 19 Ruers TJ, Wiering B, van der Sijp JR et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. J Nucl Med 2009; 50: 1036-1041
  • 20 Trastulli S, Cirocchi R, Listorti C et al. Laparoscopic vs open resection for rectal cancer: a meta-analysis of randomized clinical trials. Colorectal Dis 2012; 14: e277-296
  • 21 Twelves C, Scheithauer W, McKendrick J et al. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol 2012; 23: 1190-1197
  • 22 van Gijn W, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2012; 12: 575-582
  • 23 Yothers G, O'Connell MJ, Allegra CJ et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011; 29: 3768-3774